Accustem Sciences (ACUT) Change in Account Payables (2021 - 2026)
Accustem Sciences (ACUT) posted quarterly Change in Account Payables of $33737.0 for Q1 2026, up 573.7% year-over-year from $5007.7 in Q1 2025, and up 115.38% quarter-over-quarter from -$219378.0 in Q4 2025.
Accustem Sciences (ACUT) Change in Account Payables (2021 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Change in Account Payables for 6 consecutive years, with $33737.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 573.7% year-over-year to $33737.0; the TTM figure through Mar 2026 stood at -$59943.0 (down 207.09% YoY), while the FY2025 annual figure was -$100802.0, down 175.12% from the prior year.
- Change in Account Payables climbed to $33737.0 in Q1 2026 per ACUT's latest filing, from -$219378.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $357891.0 in Q2 2025 and bottomed at -$270009.0 in Q2 2022.
- Historically, Change in Account Payables has averaged $3310.9 across 5 years, with a median of -$7122.0 in 2025.
- On a YoY basis, Change in Account Payables climbed as much as 3529.02% in 2022 and fell as far as 713.43% in 2022.
- Accustem Sciences' Change in Account Payables stood at -$126346.0 in 2022, then surged by 56.84% to -$54529.0 in 2023, then sank by 42.43% to -$77667.0 in 2024, then slumped by 182.46% to -$219378.0 in 2025, then jumped by 115.38% to $33737.0 in 2026.
- Business Quant data shows ACUT's Change in Account Payables at $33737.0 in Q1 2026, -$219378.0 in Q4 2025, and -$232193.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - | 67,219.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,737.00 |
| Mar 31, 2026 | 33,737.00 |
| Dec 31, 2025 | -219,378.00 |
| Dec 31, 2025 | -219,378.00 |
| Sep 30, 2025 | -232,193.00 |
| Sep 30, 2025 | -232,193.00 |
| Jun 30, 2025 | 357,891.00 |
| Jun 30, 2025 | 357,891.00 |
| Mar 31, 2025 | -7,122.00 |
| Mar 31, 2025 | -7,122.00 |
| Dec 31, 2024 | -77,667.00 |
| Dec 31, 2024 | -77,667.00 |
| Sep 30, 2024 | 172,191.00 |
| Sep 30, 2024 | 172,191.00 |
| Jun 30, 2024 | -31,430.00 |
| Jun 30, 2024 | -31,430.00 |
| Mar 31, 2024 | 71,102.00 |
| Mar 31, 2024 | 71,102.00 |
| Dec 31, 2023 | -54,529.00 |
| Dec 31, 2023 | -54,529.00 |